Table 1 Laboratory data at admission
CBC (normal range) | Blood chemistry | Tumor markers | Blood culture | ||||
 RBC (400–552) | 239 × 104/mm3 |  FBS (70–110) | 179 mg/dL |  CEA (<3.4) | 0.8 ng/mL | Kocuria kristinae | (+) |
  Hb (13.2–17.2) | 6.9 g/dL |  Alp (104–338) | 501 U/L |  CA19-9 (<37) | 2.8 U/mL |  Antimicrobial susceptibilities (MIC) | μg/mL |
  Ht (40.4–51.1) | 21.9 % |  γ-GTP (5–70) | 41 U/L | Infection |  |   Penicillin | 0.12 |
 Plt (14.8–33.9) | 46.8 × 104/mm3 |  t-Bil (0.2–1.2) | 0.3 mg/dL |  HBs Ag | (−) |   Oxacillin | ≤2.0 |
 WBC (3.6–9.6) | 5.6 × 103/mm3 |  d-Bil (0–0.4) | 0.0 mg/dL |  HCV Ab | (−) |   Ampicillin | ≤0.25 |
  neu | 73.0 % |  ChE (168–470) | 123 U/L |  HTLV-I Ab | (−) |   Cefazolin | ≤8.0 |
  lym | 8.0 % |  ALT (8–42) | 24 U/L |  EBV |  |   Cefotaxime | ≤8.0 |
  mon | 13.0 % |  AST (13–33) | 37 U/L |   VCA-IgG | ×640 |   cefepime | ≤8.0 |
  eos | 6.0 % |  LDH (119–229) | 125 U/L |   VCA-IgM | ×<10 |   Cefotiam | ≤8.0 |
  bas | 0.0 % |  CPK (62–287) | 10 U/L |   EBNA | ×20 |   Cefpirome | ≤8.0 |
  aty-ly | 0.0 % |  Crn (0.6–1.1) | 10.3 mg/dL |  Mumps | (−) |   Cefozopran | ≤8.0 |
Electrolytes |  |  BUN (8–20) | 52 mg/dL |  Herpes zoster | (−) |   Cefmetazole | ≤16.0 |
 Na (136–145) | 137 mmol/L |  UA (3.4–7.8) | 8.5 mg/dL |  Parvovirus B19 | (−) |   Cefdinir | ≤1.0 |
 K (3.4–4.5) | 4.4 mmol/L |  Amy (37–125) | 71 U/L |  Syphilis | (−) |   Cefditoren | ≤1.0 |
 Cl (100–108) | 99 mmol/L |  TG (30–150) | 106 mg/dL |  QFT | (−) |   Flomoxef | ≤8.0 |
 Ca (8.7–11.0) | 10.2 mg/dL |  H-Chol (>40) | 17 mg/dL |  Candida Ab | (−) |   Imipenem/cilastatin | ≤4.0 |
 P (2.5–4.5) | 4.7 mg/dL |  L-Chol (<140) | 61 mg/dL |  β-d-glucan | (−) |   Meropenem | ≤4.0 |
 Mg (1.8–2.4) | 2.5 mg/dL | Serological examinations |  |  Chlamydia trachomatis |  |   Amoxicillin | ≤4.0 |
Proteinogram |  |  CRP (<0.3) | 35.5 mg/dL |   IgG | (−) |   Gentamicin | ≤4.0 |
 TP (6.7–8.1) | 7.1 g/dL |  SAA (<8.0) | 1843.9 mg/mL |   IgA | (−) |   Amikacin | ≤16.0 |
 Alb (3.9–4.9) | 2.6 g/dL |  MMP-3 (36.9–121.0) | 586.4 ng/mL |  Chlamydia pneumoniae |  |   Arbekacin | ≤4.0 |
 Glb | 4.5 g/dL |  CH50 (30–45) | 47.0 U/mL |   IgG | (−) |   Erythromycin | ≤0.5 |
  α1 | 11.2 % |  C3 (65–135) | 131.5 mg/dL |   IgA | (−) |   Clarithromycin | ≤2.0 |
  α2 | 16.6 % |  C4 (13–35) | 31.7 mg/dL | Synovial fluid |  |   Clindamycin | ≤0.5 |
  β | 10.7 % |  ANA | (−) |  Glossly purulent material |  |   Minocycline | ≤4.0 |
  γ | 34.3 % |  ds-DNA Ab | (−) |  WBC | 13,200 × 103/mm3 |   Linezolid | ≤2.0 |
 IgG (870–1700) | 2519 mg/dL |  SSA Ab | (−) |   neu | 95.0 % |   Vancomycin | ≤2.0 |
 IgA (110–410) | 497 mg/dL |  SSB Ab | (−) |   pla | 5.0 % |   Teicoplanin | ≤8.0 |
 IgM (35–220) | 87 mg/dL |  RF | (−) |  Crystals | (−) |   Fosfomycin | ≤4.0 |
 M-protein | (−) |  ACPA | (−) |  Culture | (−) |   Levofloxacin | ≤1.0 |
 HbA1c (4.6–6.2) | 7.9 % |  MPO-ANCA | (−) |  |  |   Sulfamethoxazole/trimethoprim | ≤2.0 |
ESR (<20) | >140 mm/h |  PR3-ANCA | (−) |  |  |   Rifampicin | ≤1.0 |